SCHEMBL4281392

SCHEMBL4281392

CSc1ccc(Cc2ccc(CO)cc2O)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 6/20 0.45
SLC6A2 P23975 2/20 0.45
SLC6A3 Q01959 2/20 0.45
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ALOX5 P09917 2/20 0.42
TBXA2R P21731 1/20 0.40
PTGER3 P43115 1/20 0.40
PTGER2 P43116 1/20 0.40
PTGDR Q13258 1/20 0.40
SLC5A2 P31639 3/20 0.40
SLC5A1 P13866 2/20 0.40
HTT P42858 1/20 0.37
KEAP1 Q14145 1/20 0.37
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289203 0.84 MAPT (0.53) MAPTMEN1KMT2AALOX5KEAP1
SCHEMBL4282537 0.79 MAPT (0.49) MAPTMEN1KMT2AALOX5HTT
SCHEMBL4292518 0.78 CYP3A4 (0.46) SLC6A4SLC6A2SLC6A3MAPTMEN1
SCHEMBL2575336 0.77 KEAP1 (0.63) SLC6A4SLC6A2SLC6A3MEN1KMT2A
SCHEMBL4293661 0.77 ESR1 (0.49) MAPTMEN1KMT2ASLC5A1
SCHEMBL564610 0.75 SLC6A4 (0.52) SLC6A4SLC6A2SLC6A3MAPTMEN1
SCHEMBL4280831 0.75 CA12 (0.50) SLC6A4SLC6A2SLC6A3MAPTMEN1
SCHEMBL4288684 0.75 BCHE (0.47) MAPTMEN1KMT2AALOX5KEAP1
SCHEMBL4292350 0.74 SLC5A2 (0.48) MAPTMEN1KMT2ASLC5A2SLC5A1
SCHEMBL11786007 0.73 TTR (0.47) MAPTMEN1KMT2AALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137499-A1 BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-05-28 US disclosed
EP-2048150-A1 BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137499-A1 BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE SLC5A1, SLC5A2, SLC2A1 SLC6A4 61/4885SLC6A2 55/4885SLC6A3 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.